Treating ALS with stem cell injections: A clinical trial
Dr. Eva Feldman, a neurologist, researcher and director of the A. Alfred Taubman Biomedical Research Institute at the University of Michigan, is the principal investigator for a landmark clinical trial involving patients with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. The FDA-approved trial, which currently is in the safety phase, involves injecting hundreds of thousands of stem cells into the spinal cords of patients with ALS. As Dr. Feldman explains in this video, it is hoped that the stem cells will provide a healthier environment for the patients' own nerve cells, preserving function and improving quality of life.
Taubman-sponsored research offers breast tumor insights
Taubman Emerging Scholar Dr. Scott Tomlins has authored a new study about phyllodes tumors.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
Familial ALS affects generations
Detroit News column featuring Dr. Eva Feldman depicts the toll of the disease on one Metro Detroit family
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.